Kidney transplant recipients (KTRs) are at increased risk of cardiovascular (CV) morbidity and mortality, and side effects induced by immunosuppressive therapy may be a major contributor to this risk, together with traditional CV risk factors. Many strategies have been considered in order to reduce CV risk in KTRs, such as steroid and/or calcineurin inhibitor (CNI) minimization, but current data are inconclusive. The introduction of mammalian target of rapamycin (mTOR) inhibitors, the cornerstone of CNI minimization, in the immunosuppressive protocol may reduce both the incidence and severity of CNI-associated side effects; however, whether this strategy has an impact on CV risk after kidney transplantation needs to be evaluated. To this end, a panel of Italian experts in the field of transplantation was convened in a series of meetings to assess the current literature on the potential of the mTOR inhibitor everolimus as a cardioprotective agent. This narrative review summarizes the panel’s round-table discussions and provides recommendations for CV risk management in KTRs.
Everolimus in kidney transplant recipients at high cardiovascular risk: a narrative review / Paoletti E.; Citterio F.; Corsini A.; Potena L.; Rigotti P.; Sandrini S.; Bussalino E.; Stallone G.; Ambrosini A.; Arnaboldi L.; Bellino D.; Boschiero L.; Caldara R.; Cannone M.; Carmellini M.; Carrano R.; Manuelli M.C.; De Cicco M.; De Rosa P.; Federico S.; Garosi G.; Iappelli M.; Iaria G.; Mastrosimone S.; Minetti E.E.; Piotti G.; Piredda G.; Pisani F.; Poli L.; Pretagostini R.; Pulizzi R.; Rampino T.; Ranghino A.; Sabbatini M.; Saracino A.; Todeschini P.; Vicedomini D.; Vinti V.; Zaza G.. - In: JN. JOURNAL OF NEPHROLOGY. - ISSN 1121-8428. - STAMPA. - 33:1(2020), pp. 69-82. [10.1007/s40620-019-00609-y]
Everolimus in kidney transplant recipients at high cardiovascular risk: a narrative review
Potena L.Membro del Collaboration Group
;Cannone M.;Todeschini P.Membro del Collaboration Group
;PAOLETTI, EDDY;RIGOTTI, PIETRO;Sandrini S.;IAPPELLI, MARTA
2020
Abstract
Kidney transplant recipients (KTRs) are at increased risk of cardiovascular (CV) morbidity and mortality, and side effects induced by immunosuppressive therapy may be a major contributor to this risk, together with traditional CV risk factors. Many strategies have been considered in order to reduce CV risk in KTRs, such as steroid and/or calcineurin inhibitor (CNI) minimization, but current data are inconclusive. The introduction of mammalian target of rapamycin (mTOR) inhibitors, the cornerstone of CNI minimization, in the immunosuppressive protocol may reduce both the incidence and severity of CNI-associated side effects; however, whether this strategy has an impact on CV risk after kidney transplantation needs to be evaluated. To this end, a panel of Italian experts in the field of transplantation was convened in a series of meetings to assess the current literature on the potential of the mTOR inhibitor everolimus as a cardioprotective agent. This narrative review summarizes the panel’s round-table discussions and provides recommendations for CV risk management in KTRs.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
